NICE approves osimertinib for advanced lung cancer.
Talha Khan
TK
Burki
D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017277:Drug Approval; D066246:ErbB Receptors / Q000235:genetics; D006297:Health Services Accessibility; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D006113:United Kingdom; D007211:Indoles; D011743:Pyrimidines
D000178:Acrylamides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D010879:Piperazines; C000596361:osimertinib; D007211:Indoles; D011743:Pyrimidines; C512478:EGFR protein, human